Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Novan, Inc. (Nasdaq: NOVN) announced a presentation by CEO Paula Brown Stafford at the virtual Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:40 AM ET. The event aims to connect management with qualified investors through one-on-one meetings.
A live video webcast of the presentation will be available on Novan's website, along with a replay accessible for 90 days. The company focuses on innovative therapeutic products for skin diseases, notably pursuing FDA approval for berdazimer gel, 10.3% for treating molluscum contagiosum, while also utilizing its NITRICIL™ technology for future treatments.
Details
News Market Reaction – NOVN
The recorded move for NOVN in the trading session of this news was -1.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Presentation with live webcast today, March 14th at 10:40 AM ET
DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference today, March 14, 2023 at 10:40 AM ET.
In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (novan.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About Novan
Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. Novan has a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams, promoting products for plaque psoriasis, rosacea and acne. The U.S. Food and Drug Administration (“FDA”) accepted for filing Novan’s New Drug Application (“NDA”) seeking approval for berdazimer gel,
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.